Lexicon Pharma (LXRX) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.42 -4.7%
Revenue Growth %: -79.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: -79.9%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $320 thousand versus the consensus estimate of $133.33 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
- Lexicon drug shows cardiac and platelet effects in preclinical studies
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
